CAH

----

Weekly Recap | Cardinal Health -5.1%, a week-long slide

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Cardinal Health (CAH) fell 5.1% this week to $234.57, while the S&P 500 lost 0.8% — leaving the stock about 4.3 percentage points behind the benchmark. The pullback built through the week: a soft open on Tuesday, a small stabilisation on Wednesday, then two consecutive down days into Friday, when the stock touched a weekly low of $232.60 and closed near it. There was no major company-specific catalyst.

The Week

Cardinal Health (CAH) fell 5.1% this week to $234.57, while the S&P 500 lost 0.8% — leaving the stock about 4.3 percentage points behind the benchmark. The pullback built through the week: a soft open on Tuesday, a small stabilisation on Wednesday, then two consecutive down days into Friday, when the stock touched a weekly low of $232.60 and closed near it. There was no major company-specific catalyst.

Analyst Ratings

Among the 18 brokers covering the name, 12 rate it buy, 3 rate it overweight, and 3 rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target sits at $270.94, about 15.5% above spot. Targets range from $235 to $292, a moderate spread. The stock ranks first among nine companies in the medical products distribution industry.

The Week Ahead

US macro data dominate the coming week. On Tuesday 15 September, the New York Fed manufacturing index is due, with a prior of 20.6 and a forecast of 14.75. Wednesday 16 September brings retail sales, retail sales excluding autos, and import prices, with headline retail sales seen rising 0.9% after a 0.6% decline. These prints will shape the read on consumer resilience.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.